



February 2020

Dear 2020 **HCPCS Level II Coders' Desk Reference** Customer,

Our postproduction quality process identified incorrect information in your 2020 **HCPCS Level II Coders' Desk Reference**. These are noted below. Please make the necessary corrections in your HCPCS Level II product.

If you have any further questions, our customer service team can assist you: 1.800.464.3649, option 1.

We apologize for any inconvenience these errors may have caused. Thank you for your patience and support of our ongoing effort to deliver high-quality products. We appreciate your business.

Sincerely,

Optum360

www.optum360coding.com

The following code/lay description was incorrectly noted in the chapter entitled "HCPCS Lay Descriptions":

C1824 Generator, cardiac contractility modulation (implantable)

A cardiac contractility modulation generator is a small implantable device, similar to a pacemaker, intended for the treatment of chronic heart failure in patients who are symptomatic despite appropriate medical treatment. In contrast to a pacemaker or a defibrillator, the system is designed to modulate the strength of contraction of the heart muscle rather than the rhythm. Typically implanted in the right pectoral region, this minimally invasive device is connected to three standard leads (electrodes) that are used to sense atrial and ventricular activity. An electrode in the right atrium and two in the right ventricle of the heart ensure the precise timing of the cardiac contractility modulation (CCM) signals, delivering them just after the heart contracts (the absolute refractory period). The U.S. Food and Drug Administration (FDA) granted breakthrough device exemption for the OPTIMIZER® Smart Implantable Pulse Generator (Impulse Dynamics, Orangeburg, NY) with approved use in the treatment of individuals with chronic, moderate-to-severe (New York Heart Failure [NYHA] Class III or ambulatory Class IV) heart failure (HF) who remain symptomatic despite guideline-directed medical therapy (GDMT). Recipients must be in normal sinus rhythm with left ventricular ejection fraction (LVEF) from 25 to 45 percent and not considered a candidate for cardiac resynchronization therapy (CRT) to restore normal heart rhythm. The CCM delivers electrical signals to the ventricles during the ventricular absolute refractory period. The expected result is improvement in six-minute hall walking distance, quality of life, functional status, and exercise tolerance.

Also in this chapter, the following code/lay description was missing:

C9747 Ablation of prostate, transrectal, high intensity focused ultrasound (HIFU), including imaging guidance

High-intensity focused ultrasound (HIFU), the focusing of sound waves to create heat at a desired focal point, is used to treat several prostate disorders, including benign prostatic hyperplasia (BPH) and prostate cancer. It is a noninvasive and radiation-free method of treating prostate disease by destroying prostate tissue, usually in a single session. In addition to being noninvasive, HIFU has a low morbidity rate and short recovery time, and it enables a quick return to daily activities. Under real-time imaging guidance, the physician focuses high-intensity ultrasound energy on targeted tissue in the prostate. The HIFU heats and ablates (destroys) the tissue. This is repeated until all desired tissue is ablated. Depending on the disease being treated, the physician may ablate only a precise section of the prostate or the entire prostate. Treatment may be repeated, if necessary, and can be used to treat patients that have failed radiation treatment.

For customer service, call 1.800.464.3649, option 1.